Kronos Bio Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Kronos Bio, Inc. (Nasdaq: KRON) announced participation in two upcoming investor conferences. The management team will engage in fireside chats at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 a.m. ET, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 11:20 a.m. ET. These discussions will be webcast live on the company's website, with replays available for one month after each event. Kronos Bio focuses on developing cancer therapies, including SYK inhibitors and CDK9 inhibitors, to target specific mutations in cancer.

SAN MATEO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

• Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 10:30 a.m. ET; and
• Goldman Sachs 42^nd Annual Global Healthcare Conference on Wednesday, June 9, 2021, at 11:20 a.m. ET.

The fireside chats will be webcast live from the Investors & Media section of the company’s website at www.kronosbio.com. A replay of the webcast will be archived and available for one month following the event.

About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio is developing a portfolio of spleen tyrosine kinase (SYK) inhibitors, entospletinib (ENTO) and lanraplenib (LANRA), for the treatment of NPM1-mutated and FLT3-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-dependent solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

Company contact:
Stephanie Yao
Executive Director, Investor Relations and Corporate Communications
650-525-6605
syao@kronosbio.com

Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

FAQ

What conferences is Kronos Bio participating in June 2021?

Kronos Bio will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021.

What time is the Jefferies Virtual Healthcare Conference for Kronos Bio?

The Jefferies Virtual Healthcare Conference will take place at 10:30 a.m. ET on June 2, 2021.

What time is the Goldman Sachs Conference for Kronos Bio?

The Goldman Sachs 42nd Annual Global Healthcare Conference will be held at 11:20 a.m. ET on June 9, 2021.

Where can I watch the Kronos Bio fireside chats?

The fireside chats can be watched live on the Kronos Bio website in the Investors & Media section.

What is the focus of Kronos Bio's drug development?

Kronos Bio focuses on developing therapies targeting dysregulated transcription factors and includes SYK inhibitors for specific types of acute myeloid leukemia.